361 reports of this reaction
4.2% of all REGADENOSON reports
#3 most reported adverse reaction
INJECTION SITE EXTRAVASATION is the #3 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 361 FDA adverse event reports linking REGADENOSON to INJECTION SITE EXTRAVASATION. This represents approximately 4.2% of all 8,610 adverse event reports for this drug.
Patients taking REGADENOSON who experience injection site extravasation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE EXTRAVASATION is moderately reported among REGADENOSON users, representing a notable but not dominant share of adverse events.
In addition to injection site extravasation, the following adverse reactions have been reported for REGADENOSON:
INJECTION SITE EXTRAVASATION has been reported as an adverse event in 361 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE EXTRAVASATION accounts for approximately 4.2% of all adverse event reports for REGADENOSON, making it one of the most commonly reported side effect.
If you experience injection site extravasation while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.